ZYBT חוב כולל להון Zhengye Bio

Zhengye Biotechnology adheres to standard environmental regulations, ensuring the safe disposal of bio-waste and energy efficiency across its production facilities. The business relies on partnerships with veterinary clinics to develop diagnostic systems and new vaccines. This price chart reflects a total debt-to-equity ratio of 0.31, while drug production is automated via robotics to reduce manual labor.

Zhengye Biotechnology (ZYBT) possesses limited pricing power amid the crisis in China's swine industry, which directly impacts the company's ability to service its obligations. Under these conditions, the company's financial leverage chart reflects the business's dependence on borrowed funds relative to its equity. This ratio measures the total debt load, determining the issuer's degree of financial autonomy. An increase in this ratio signals a risk of bankruptcy. Analyzing the trend on the chart allows for the timely identification of a value trap.